3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Unknown
1
Terminated
1
Suspended
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
41
Other solid neoplasm
41
Gynecologic
7
Gastrointestinal
7
Breast
6
Lymphoid
2
Head & Neck
2
Genitourinary
2
Sarcoma
1
NET
1
Endocrine
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
71
Pituitary Neoplasms
47
Thyroid Cancer, Papillary
28
Multiple Endocrine Neoplasia Type 1
21
Carcinoma, Neuroendocrine
21
Pheochromocytoma
18
Paraganglioma
14
Thyroid Neoplasms
13
Carcinoid Tumor
13
Neoplasm Metastasis
12
Differentiated Thyroid Cancer
12
Adrenocortical Carcinoma
11
Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Pancreatic Neoplasms
8
Insulinoma
8
Adrenal Gland Neoplasms
8
Pituitary Diseases
6
Lung Neoplasms
6
Hyperaldosteronism
6
Gastro-enteropancreatic neuroendocrine tumor
6
Acromegaly
6
Stomach Neoplasms
5
Prostatic Neoplasms
5
Prolactinoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Breast Neoplasms
5
Adrenocortical Adenoma
5
Adenoma, Islet Cell
5
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Mesothelioma, Malignant
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled